Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Boettcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda

Journal article

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Boettcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse Show all

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

DOI: 10.1016/S1470-2045(16)30019-5

University of Melbourne Researchers

John Seymour Author Medicine - St Vincent's Hospital

Andrew Roberts Author

Grants

Funding Acknowledgements

AbbVie and Genentech/Roche provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review, and approval of the manuscript. Venetoclax is being developed in a collaboration between AbbVie and Genentech. We thank the patients who participated in this trial and their families; the investigators, study coordinators, and support staff at the clinical sites; AbbVie and Genentech venetoclax team members; Jaimee Glasgow for medical writing support, Joseph Beason and Jingwen Jia for data programming support, Jennifer Arzt and Mia Poteracki for clinical trial operational support, and Andrew Roberts for data review support (all employees of AbbVie).